Drug Trial Radar · NCT06467084
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 1, 2024
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Conditions
- Hereditary Angioedema
Interventions
KVD900 150 mgDrug
KVD900 Tablet 150 mg (2 x 75 mg)
KVD900 300 mgDrug
KVD900 Tablet 300 mg (1 x 300 mg)
KVD900 600 mgDrug
KVD900 Tablet 600 mg (2 x 300 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of IMP until the Final/Early Termination (ET) Visit, up to a maximum of 54 weeks.
Locations
24 sites in 7 countries. Site status is shown where the registry gives one.
KalVista Investigative Site
Birmingham, Alabama
KalVista Investigative Site
Scottsdale, Arizona
KalVista Investigative Site
San Diego, California
KalVista Investigative Site
Santa Monica, California
KalVista Investigative Site
Evansville, Indiana
KalVista Investigative Site
Wheaton, Maryland
KalVista Investigative Site
St Louis, Missouri
KalVista Investigative Site
Toledo, Ohio
KalVista Investigative Site
Hershey, Pennsylvania
KalVista Investigative Site
Dallas, Texas
KalVista Investigative Site
Edmonton, Alberta, Canada
KalVista Investigative Site
Lille, France
KalVista Investigative Site
Marseille, France
KalVista Investigative Site
Paris, France
KalVista Investigative Site
Frankfurt am Main, Germany
KalVista Investigative Site
Frankfurt am Main, Germany
KalVista Investigative Site
Haifa, Israel
KalVista Investigative Site
Petah Tikva, Israel
KalVista Investigative Site
Tel Aviv, Israel
KalVista Investigative Site
Milan, Italy
KalVista Investigative Site
Padova, Italy
KalVista Investigative Site
Rome, Italy
KalVista Investigative Site
Kawagoe, Japan
KalVista Investigative Site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.